Navigation Links
Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research
Date:11/3/2008

NEW YORK, Nov. 3 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation today announced the availability of up to $11 million in 2009 funding for research toward transformative treatments and a cure for Parkinson's disease.

Funding is open to academic and industry researchers through the Foundation's Pipeline Programs, five separate initiatives that stoke research at every stage of the PD drug development pipeline. This includes early-stage discovery research, translational studies that can carry identified hits forward to the next stage of development, and proof-of-principle/first-in-human clinical trials.

"The Michael J. Fox Foundation is committed to prioritizing and aggressively driving research with potential to significantly improve patients' quality of life," said Katie Hood, the Foundation's CEO. "Each one of our Pipeline Programs is a unique and complementary expression of our overarching mission -- identifying and enabling the critical ideas, teams and projects that will carry the field over the finish line to make Parkinson's a disease of the past."

There are a total of five Pipeline Programs: three annually recurring initiatives known collectively as The Edmond J. Safra Core Programs for PD Research; Novel Approaches to Drug Discovery for PD, a collaboration made possible by co-funding from Elan (NYSE: ELN); and the industry-exclusive Therapeutics Development Initiative.

Brief program descriptions follow. Full details are available at http://www.michaeljfox.org/research.cfm. The Foundation has redesigned its Funding Opportunities page to enhance ease of use and provide researchers with a better understanding of how various programs fit into the larger context of the MJFF portfolio.

Rapid Response Innovation Awards, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

No deadline; applications accepted at any time

Rapid Response Innovation Awards provide up to $75,000 for projects with little to no existing preliminary data, but with potential to significantly impact understanding or treatment of Parkinson's disease. MJFF is eager to fund high-risk, high-reward projects tackling critical scientific roadblocks to open new avenues for PD therapy development. Research proposals may be submitted at any time and funding decisions are made within six weeks of receiving the application.

Target Validation, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

Deadline: 6 p.m. ET, Tuesday, January 6, 2009

Funding anticipated: May 2009

Target Validation provides awards of up to $250,000 to validate the therapeutic potential of scientific discoveries and push them one step closer to the clinic. While research continues to identify new genetic, cellular and biological targets for therapeutic intervention to benefit PD patients, the translation of these discoveries into practical treatments requires additional applied work. Target Validation funds this work with the ultimate goal of 'de-risking' potential investment in the most promising targets by biotech and pharmaceutical companies, who are generally best-suited to carry promising therapies forward into the clinic.

Clinical Intervention Awards, An Edmond J. Safra Core Program for PD Research Total available funding: $3 million

An Edmond J. Safra Core Program for PD Research

Deadline: 6 p.m. ET, Thursday, March 12, 2009

Funding anticipated: July 2009

The Clinical Intervention Awards drive clinical intervention trials of promising therapeutic approaches with potential to significantly improve the treatment of PD. Ideal proposals will focus on tests of novel treatments that can slow or halt disease progression, or that can greatly reduce PD motor and non-motor symptoms beyond (and without the complications of) current standards of care. There is no pre-set budget limitation for applications under this initiative.

Novel Approaches to Drug Discovery for PD

A collaboration with Elan Pharmaceuticals, Inc.

Total available funding: $1.5 million

Deadline: 6 p.m. ET, Tuesday, February 10, 2009

Funding Anticipated: July 2009

With a strong focus on the development of disease-modifying therapies for PD, Novel Approaches to Drug Discovery provides funding for projects of up to one year's duration. Ideal proposals will focus on efforts to develop promising biological targets into novel disease-modifying therapeutic strategies. Novel Approaches holds unique potential to provide awardees from both academic and biotech institutions with a clear opportunity for follow-on funding and collaboration for further development. Elan Pharmaceuticals, Inc., a neuroscience-based biotechnology company committed to developing novel approaches for neurodegenerative diseases, has an option for a right of first negotiation for any promising approaches or materials that arise out of this program. There is no pre-set budget limitation for applications under this initiative.

Therapeutics Development Initiative

Total available funding: $2.5 million, exclusively to industry

Deadline: 6 p.m. ET, Tuesday, January 20, 2009

Funding Anticipated: June 2009

The Therapeutics Development Initiative (TDI) seeks to stimulate preclinical Parkinson's disease research projects of up to two years' duration at for-profit institutions. There is no pre-set budget limitation for applications under this initiative. The program prioritizes key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.

Applications for all programs must be submitted through http://www.michaeljfox.org.

Pre-proposals (required for all programs except Rapid Response Innovation Awards) will be reviewed by the Foundation's scientific staff and a panel of scientific experts. Applicants whose pre-proposals meet the review criteria will be invited to submit full proposals. For each program, a conference call with MJFF Research Programs staff to further clarify the aims and goals will be held in advance of the application deadline. Date and time details for each conference call are available at http://www.michaeljfox.org.

Additional research funds for the coming year will be announced at later dates under the Foundation's 2009 Critical Challenges initiatives -- programs that provide funding for top MJFF research priorities and areas of particular emphasis.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $128 million in research to date.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
(Date:6/8/2017)... , June 8, 2017  StatLab ... leading developer and manufacturer of diagnostic supplies ... today that Cressey & Company LP ("Cressey ... has completed a growth-focused investment in the ... majority ownership position from selling shareholder, Prairie ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. ... for leading-edge care, whether or not they have a referral. Dr. Kejriwal offers ... iPlus™ laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could reduce ... in their throats when they need help breathing or to provide medication. Sometimes, ...
(Date:6/20/2017)... ... 20, 2017 , ... Total Security Integrated Systems, one of ... partner of choice by Amtrak to fulfill several projects in various Northeast US ... intercity service in the contiguous United States. Security Executives at the company were ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... bedside, would like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN ... whose insight and expertise in healthcare will provide invaluable direction for the company,” ...
Breaking Medicine News(10 mins):